Literature DB >> 3716882

Expansion of extracellular volume in early polycystic kidney disease.

H Danielsen, E B Pedersen, A H Nielsen, P Herlevsen, H J Kornerup, V Posborg.   

Abstract

Blood volume (BV), extracellular volume (ECV), blood pressure (BP), creatinine clearance (CCr), plasma levels of angiotensin II (AII), aldosterone (Aldo) and arginine vasopressin (AVP), and serum osmolality (Sosm) were determined in 18 patients with adult polycystic kidney disease, 8 normotensive (group I), 10 hypertensive (group II), and in 11 control subjects (group III). ECV but not BV was increased in group I compared with group III, whereas BV and ECV did not differ significantly between groups II and III. In group II, Aldo and AVP were increased and AII tended to be increased, while in group I the hormone levels did not differ significantly from those in group III. Sosm did not differ significantly between the groups. In the combined patient group, CCr correlated positively with BV and ECV and negatively with BP. In the patients, AII and AVP were positively correlated with BP but not with CCr. The results suggest that both the renin-angiotensin system and AVP might be involved in the BP elevation, whereas expansion of ECV can be found without an increase in BP.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3716882     DOI: 10.1111/j.0954-6820.1986.tb03330.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  12 in total

Review 1.  Vasopressin and disruption of calcium signalling in polycystic kidney disease.

Authors:  Fouad T Chebib; Caroline R Sussman; Xiaofang Wang; Peter C Harris; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

Review 2.  Potential pharmacological interventions in polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Robert W Schrier
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin.

Authors:  Gail A Reif; Tamio Yamaguchi; Emily Nivens; Hiroyuki Fujiki; Cibele S Pinto; Darren P Wallace
Journal:  Am J Physiol Renal Physiol       Date:  2011-08-03

4.  Collecting duct cells that lack normal cilia have mislocalized vasopressin-2 receptors.

Authors:  Takamitsu Saigusa; Ryan Reichert; Jennifer Guare; Brian J Siroky; Monika Gooz; Stacy Steele; Robert A Fenton; P Darwin Bell; Robert J Kolb
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-28

Review 5.  Cyclic AMP-mediated cyst expansion.

Authors:  Darren P Wallace
Journal:  Biochim Biophys Acta       Date:  2010-11-28

Review 6.  Polycystic kidney disease: pathogenesis and potential therapies.

Authors:  Vinita Takiar; Michael J Caplan
Journal:  Biochim Biophys Acta       Date:  2010-12-10

7.  Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.

Authors:  Esther Meijer; Stephan J L Bakker; Eric J van der Jagt; Gerjan Navis; Paul E de Jong; Joachim Struck; Ron T Gansevoort
Journal:  Clin J Am Soc Nephrol       Date:  2010-10-07       Impact factor: 8.237

Review 8.  Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease.

Authors:  Tevfik Ecder; Robert W Schrier
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

Review 9.  Vasopressin antagonists in polycystic kidney disease.

Authors:  Vicente E Torres
Journal:  Semin Nephrol       Date:  2008-05       Impact factor: 5.299

10.  Calmodulin-sensitive adenylyl cyclases mediate AVP-dependent cAMP production and Cl- secretion by human autosomal dominant polycystic kidney cells.

Authors:  Cibele S Pinto; Gail A Reif; Emily Nivens; Corey White; Darren P Wallace
Journal:  Am J Physiol Renal Physiol       Date:  2012-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.